Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Belinostat and bortezomib may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth. Giving belinostat together with bortezomib may kill more
cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of
giving belinostat together with bortezomib in treating patients with relapsed or refractory
acute leukemia or myelodysplastic syndrome.